The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder

Uckun Z., Baskak B., ÖZEL KIZIL E. T., Ozdemir H., ÖZGÜVEN H., SÜZEN H. S.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, cilt.40, sa.6, ss.672-679, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40 Sayı: 6
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1111/jcpt.12320
  • Dergi Adı: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.672-679
  • Anahtar Kelimeler: citalopram, CYP2C19, genetic polymorphisms, major depressive disorder, PROTON PUMP INHIBITORS, CYP2C19-ASTERISK-17 ALLELE, GENETIC-POLYMORPHISM, PSYCHIATRIC-PATIENTS, RACEMIC CITALOPRAM, GENOTYPE, ESCITALOPRAM, POPULATION, PHARMACOKINETICS, 2C19
  • Ankara Üniversitesi Adresli: Evet

Özet

What is known and objective: Genetic variations in drug-metabolizing enzyme genes change drug pharmacokinetics and response. CYP2C19 is a clinically important enzyme that metabolizes citalopram (CIT). The objective of this study was to determine CYP2C19 genetic polymorphisms and to evaluate the impact of these polymorphisms on the metabolism of citalopram in a sample of the Turkish population. We also assessed *17 polymorphism in healthy subjects in this population.